These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 1349263

  • 1. Synergistic interactions of D1- and D2-selective dopamine agonists in animal models for Parkinson's disease: sites of action and implications for the pathogenesis of dyskinesias.
    Robertson HA.
    Can J Neurol Sci; 1992 Feb; 19(1 Suppl):147-52. PubMed ID: 1349263
    [Abstract] [Full Text] [Related]

  • 2. Receptor subtype-specific dopaminergic agents and unconditioned behavior.
    Beninger RJ, Mazurski EJ, Hoffman DC.
    Pol J Pharmacol Pharm; 1991 Feb; 43(6):507-28. PubMed ID: 1687945
    [Abstract] [Full Text] [Related]

  • 3. [Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].
    Damier P, Tremblay L, Féger J, Hirsch EC.
    Rev Neurol (Paris); 2000 Mar; 156(3):224-35. PubMed ID: 10740093
    [Abstract] [Full Text] [Related]

  • 4. D1 dopamine receptor stimulation enables the postsynaptic, but not autoreceptor, effects of D2 dopamine agonists in nigrostriatal and mesoaccumbens dopamine systems.
    Wachtel SR, Hu XT, Galloway MP, White FJ.
    Synapse; 1989 Mar; 4(4):327-46. PubMed ID: 2532422
    [Abstract] [Full Text] [Related]

  • 5. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
    Darmopil S, Martín AB, De Diego IR, Ares S, Moratalla R.
    Biol Psychiatry; 2009 Sep 15; 66(6):603-13. PubMed ID: 19520364
    [Abstract] [Full Text] [Related]

  • 6. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys.
    Kanda T, Jackson MJ, Smith LA, Pearce RK, Nakamura J, Kase H, Kuwana Y, Jenner P.
    Exp Neurol; 2000 Apr 15; 162(2):321-7. PubMed ID: 10739638
    [Abstract] [Full Text] [Related]

  • 7. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway.
    Sonsalla PK, Manzino L, Heikkila RE.
    J Pharmacol Exp Ther; 1988 Oct 15; 247(1):180-5. PubMed ID: 2971797
    [Abstract] [Full Text] [Related]

  • 8. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT, White FJ.
    Synapse; 1992 Mar 15; 10(3):206-16. PubMed ID: 1532677
    [Abstract] [Full Text] [Related]

  • 9. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1999 Feb 15; 155(2):204-20. PubMed ID: 10072296
    [Abstract] [Full Text] [Related]

  • 10. DOPA-induced "peak dose" dyskinesia: clues implicating D2 receptor-mediated mechanisms using dopaminergic agonists in MPTP monkeys.
    Blanchet PJ, Gomez-Mancilla B, Bédard PJ.
    J Neural Transm Suppl; 1995 Feb 15; 45():103-12. PubMed ID: 8748615
    [Abstract] [Full Text] [Related]

  • 11. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T.
    Mol Pharmacol; 1996 Nov 15; 50(5):1073-9. PubMed ID: 8913337
    [Abstract] [Full Text] [Related]

  • 12. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P, Bédard PJ, Britton DR, Kebabian JW.
    J Pharmacol Exp Ther; 1993 Oct 15; 267(1):275-9. PubMed ID: 7901395
    [Abstract] [Full Text] [Related]

  • 13. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
    Hu XT, White FJ.
    Synapse; 1994 May 15; 17(1):43-61. PubMed ID: 7913772
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
    Mercuri NB, Bernardi G.
    Trends Pharmacol Sci; 2005 Jul 15; 26(7):341-4. PubMed ID: 15936832
    [Abstract] [Full Text] [Related]

  • 18. The differential effects of 5-HT(1A) receptor stimulation on dopamine receptor-mediated abnormal involuntary movements and rotations in the primed hemiparkinsonian rat.
    Dupre KB, Eskow KL, Negron G, Bishop C.
    Brain Res; 2007 Jul 16; 1158():135-43. PubMed ID: 17553470
    [Abstract] [Full Text] [Related]

  • 19. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
    Carlsson T, Carta M, Muñoz A, Mattsson B, Winkler C, Kirik D, Björklund A.
    Brain; 2009 Feb 16; 132(Pt 2):319-35. PubMed ID: 19039008
    [Abstract] [Full Text] [Related]

  • 20. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
    Delfino MA, Stefano AV, Ferrario JE, Taravini IR, Murer MG, Gershanik OS.
    Behav Brain Res; 2004 Jul 09; 152(2):297-306. PubMed ID: 15196797
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.